

Table SI. p-values and hazard ratios (HRs) including 95% (CIs) of all predictors tested for drug survival for the separate discontinuation reasons in 107 patients with localized scleroderma (LoS) treated with methotrexate (MTX)

| Sign                                                      | I – Treatment failure (34 events) |                     |              |                     | Ia – Side effects (20 events) |                     |                |                     | Ib – Treatment ineffectiveness (18 events) II – Remission (48 events) |         |         |         |
|-----------------------------------------------------------|-----------------------------------|---------------------|--------------|---------------------|-------------------------------|---------------------|----------------|---------------------|-----------------------------------------------------------------------|---------|---------|---------|
|                                                           | I – Treatment failure (34 events) |                     |              |                     |                               |                     |                |                     |                                                                       |         |         |         |
|                                                           | p-value                           | Exp (B)             | p-value      | Exp (B)             | p-value                       | Exp (B)             | p-value        | Exp (B)             | p-value                                                               | Exp (B) | p-value | Exp (B) |
| Age at onset "5 year intervals"                           | 0.362                             | 0.958 (0.874;1.051) | 0.215        | 0.926 (0.820;1.046) | 0.533                         | 0.961 (0.846;1.090) | <b>0.011</b>   | 0.898 (0.827;0.976) |                                                                       |         |         |         |
| Dichotomous (adult vs. paediatric)                        | 0.230                             | 0.519 (0.223;1.207) | <b>0.192</b> | 0.470 (0.152;1.459) | <b>0.127</b>                  | 0.412 (0.132;1.288) | <b>0.069</b>   | 0.439 (0.180;1.066) |                                                                       |         |         |         |
| Age at MTX "5 year intervals"                             | 0.667                             | 0.977 (0.880;1.085) | 0.560        | 0.960 (0.838;1.101) | 0.971                         | 1.003 (0.868;1.159) | <b>0.004</b>   | 0.874 (0.797;0.959) |                                                                       |         |         |         |
| Treatment initiation delay "1 year intervals"             | <b>0.079</b>                      | 1.044 (0.995;1.096) | <b>0.034</b> | 1.062 (1.005;1.122) | <b>0.029</b>                  | 1.065 (1.006;1.126) | 0.491          | 1.023 (0.958;1.093) |                                                                       |         |         |         |
| Treatment initiation delay, dichotomous (<2 vs. >2 years) | <b>0.142</b>                      | 0.603 (0.307;1.184) | <b>0.196</b> | 0.558 (0.231;1.350) | <b>0.071</b>                  | 0.417 (0.162;1.078) | <b>0.172</b>   | 0.670 (0.377;1.190) |                                                                       |         |         |         |
| Subtypes                                                  |                                   |                     |              |                     |                               |                     |                |                     |                                                                       |         |         |         |
| Circumscribed superficial, dichotomous (yes vs. no)       | 0.020                             | 0.370 (0.160;0.854) | <b>0.131</b> | 0.455 (0.163;1.266) | <b>0.049</b>                  | 0.286 (0.082;0.996) |                | 0.886 (0.495;1.584) |                                                                       |         |         |         |
| En Coup De Sabre, dichotomous (yes vs. no)                | 0.517                             | 0.047               | 0.613        | 0.047               | 0.653                         | 0.047               | 0.928          | 0.912 (0.125;6.666) |                                                                       |         |         |         |
| Generalized LoS, dichotomous (yes vs. no)                 | <b>0.088</b>                      | 1.815 (0.914;3.597) | 0.448        | 1.495 (0.568;3.597) | 0.294                         | 1.667 (0.643;4.310) | 0.971          | 0.988 (0.508;1.919) |                                                                       |         |         |         |
| Deep LoS, dichotomous (yes vs. no)                        | 0.482                             | 0.708 (0.270;1.855) | 0.527        | 0.668 (0.190;2.336) | 0.768                         | 1.186 (0.381;3.690) | <b>0.007</b>   | 0.194 (0.059;0.636) |                                                                       |         |         |         |
| Linear LoS on the limbs/trunk, dichotomous (yes vs. no)   | 0.779                             | 0.896 (0.418;1.923) | 0.858        | 1.092 (0.418;2.849) | 0.904                         | 0.938 (0.334;2.639) | <b>0.076</b>   | 1.706 (0.945;3.077) |                                                                       |         |         |         |
| Fol acid, dichotomous (yes vs. no)                        | <b>0.006</b>                      | 0.368 (0.180;0.754) | <b>0.061</b> | 0.400 (0.153;1.044) | <b>0.119</b>                  | 0.446 (0.162;1.230) | < <b>0.001</b> | 0.198 (0.104;0.376) |                                                                       |         |         |         |
| Calendar year at MTX initiation "1 year intervals"        | 0.413                             | 0.974 (0.915;1.037) | 0.968        | 0.998 (0.919;1.084) | 0.975                         | 1.001 (0.915;1.096) | < <b>0.001</b> | 0.859 (0.811;0.909) |                                                                       |         |         |         |
| Sex, dichotomous (♂ vs. ♀)                                | 0.663                             | 0.829 (0.385;1.788) | 0.909        | 1.058 (0.401;2.789) | 0.213                         | 0.452 (0.129;1.577) | 0.836          | 0.935 (0.493;1.773) |                                                                       |         |         |         |
| Concomitant cutaneous autoimmune disease                  | 0.203                             | 1.677 (0.756;3.731) | 0.525        | 1.431 (0.474;4.310) | 0.436                         | 1.563 (0.509;4.785) | 0.890          | 1.059 (0.469;2.387) |                                                                       |         |         |         |
| Concomitant autoimmune disease dichotomous (present)      | 0.560                             | 0.789 (0.355;1.751) | 0.711        | 0.824 (0.297;2.294) | 0.556                         | 0.714 (0.233;2.193) | <b>0.004</b>   | 0.275 (0.115;0.655) |                                                                       |         |         |         |
| Antinuclear antibodies, dichotomous                       | 0.746                             | 1.148 (0.498;2.644) | 0.261        | 0.423 (0.094;1.894) | <b>0.083</b>                  | 2.530 (0.886;7.227) | 0.798          | 0.911 (0.446;1.859) |                                                                       |         |         |         |

Predictors with a p-value ≤0.2 (**bold**) were up for selection to be imported in a multivariable model. The cells shaded grey represent the predictors that were included in the multivariate Cox regression analyses.